Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the tolerability and safety of SAD448 and explore the compound's effect on intraocular pressure in subjects with ocular hypertension.

• Phase: Phase 1

Details

• Lead Sponsor: Novartis

Criteria

Key inclusion criteria:

• Males and females, 18 - 65 years of age, with ocular hypertension

• Females must be post-menopausal or surgically sterile

Key exclusion criteria:

• Diagnosis of glaucoma in either eye

• A history of or current eye conditions or medical problems that would prohibit the use of an investigational drug